Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs VCEL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VCEL Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

VCEL Overall Winner 6-Pillar Tally: NTLA 1 – 5 VCEL Matrix Metrics: NTLA 1 – 9 VCEL

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas VCEL carries 34.8/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin).

  • Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.3% vs. -826.0% operating margin) and revenue trajectory (+26.5% vs. -48.0% YoY).
  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 73.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs VCEL
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
50.7 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.2%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $11.58 · SMA50: $11.86
VCEL NASDAQ Head-to-Head Winner
Vericel Corporation
Biological Products, (No Disgnostic Substances)
$57.27
+0.54% 1D
Market Cap $2.9B
TTM Revenue $324M
Forward P/E 60.5x
Beta / 30D Vol 0.30β · 74% Vol
Unified Composite Score
34.8 / 100 SELL
Tech 50.0 Fund 34.0 Flow 70.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.4% over 20 days), RSI 74
RSI-14: 73.9 · SMA20: $47.98 · SMA50: $43.13

6-Pillar Scorecard Institutional Category Breakdown (NTLA 1 – 5 VCEL)

Columns: Metric · NTLA · VCEL
1. Valuation Multiples VCEL
Forward P/E N/M 60.5x
Trailing P/E N/M 90.3x
PEG Ratio N/M N/M
EV / Revenue 29.1x 9.0x
2. Growth & Scale VCEL
Revenue Growth (YoY) -48.0% +26.5%
Earnings Growth (YoY) +0.0% +170.0%
TTM Revenue (USD) $53M $324M
Market Cap $1.5B $2.9B
3. Profitability & Quality VCEL
Gross Margin N/A 74.5%
Operating Margin -826.0% 8.3%
Net Profit Margin 0.0% 10.3%
Return on Equity (ROE) -62.6% 9.4%
4. Balance Sheet & Cash Flow VCEL
Cash Generation (TTM) -$358M $58M
Cash Flow Margin N/A 17.9%
Net Cash / Leverage $74M Net Debt (0.38x D/E) $43M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VCEL
Options Structure Phase BREAKDOWN SURGE
Current IV / %ile 101.3% (78th %ile) 44.1% (13th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown ACCUMULATION · Markup
6. R&D & Supply-Chain Moat NTLA
OpEx & R&D Intensity N/A 66.2% of Rev ($215M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (1) vs VCEL (9)
Institutional Metric NTLA VCEL Criterion Row Edge
Market Capitalization
Scale
$1.5B $2.9B Larger Scale VCEL
Trailing P/E Ratio
Valuation
N/M 90.3x Lower Multiple VCEL
Forward P/E Ratio
Valuation
N/M 60.5x Lower Multiple VCEL
Revenue Growth (YoY)
Growth
-48.0% +26.5% Higher Growth VCEL
Operating Margin (TTM)
Profitability
-826.0% 8.3% Higher Margin VCEL
Net Profit Margin
Profitability
0.0% 10.3% Higher Margin VCEL
Return on Equity (ROE)
Capital Efficiency
-62.6% 9.4% Higher ROE VCEL
52-Week Range Position
Momentum
20% ($8–$18) 92% ($29–$60) Stronger Trend VCEL
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 0.30β · 74% Vol Lower Realized Risk VCEL
Unified Institutional Score
Composite Signal
50.7 / 100 (HOLD) 34.8 / 100 (SELL) Higher Composite NTLA
Trailing 12M Revenue (USD)
Operating Scale
$53M $324M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 9.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) $58M ($43M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VCEL +55.14 pp
NTLA: -12.43% · VCEL: +42.71%
3M Horizon VCEL +43.18 pp
NTLA: -13.79% · VCEL: +29.39%
6M Horizon VCEL +85.44 pp
NTLA: -21.2% · VCEL: +64.24%
1Y Horizon VCEL +28.41 pp
NTLA: +15.34% · VCEL: +43.75%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue VCEL Revenue NTLA Op. Margin VCEL Op. Margin Margin Leader
FY2018 $30M $90M -298.6% -4.3% VCEL
FY2019 $40M $120M -246.8% -9.5% VCEL
FY2020 $60M $120M -235.5% 1.9% VCEL
FY2021 $30M $150M -810.4% -5.1% VCEL
FY2022 $50M $160M -879.0% -10.4% VCEL
FY2023 $40M $200M -1420.5% -3.3% VCEL
FY2024 $60M $240M -923.1% 1.9% VCEL
FY2025 $70M $280M -651.7% 4.0% VCEL

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VCEL SURGE
5d in phase · OBV ACCUMULATION
Current IV 44.1%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact VCEL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
VCEL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and 8.3% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($215M)
90D Engineering Disclosures 0 Published

Investor FAQ NTLA vs VCEL Key Questions & Quantitative Answers

As of Nov 16, 2026, Vericel Corporation (VCEL) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 50.7/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas VCEL carries 34.8/100 (SELL) at $57.27 (60.5x Forward P/E, 8.3% operating margin). Composite vs. Pillar Nuance: While NTLA currently prints a higher short-term Unified Composite Score (50.7/100 HOLD vs. VCEL 34.8/100 SELL), VCEL captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.3% vs. -826.0% operating margin) and revenue trajectory (+26.5% vs. -48.0% YoY). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.0); meanwhile VCEL trades in a Markup technical trend (SURGE options phase, RSI 73.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VCEL leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with VCEL at +26.5% YoY revenue growth and +170.0% YoY earnings growth on $324M TTM revenue (74.5% gross margin, 8.3% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while VCEL shifted +211.1%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus 66.2% of Rev ($215M) (0 disclosures) for VCEL.

VCEL screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas VCEL trades at 60.5x Forward P/E, 90.3x Trailing P/E, N/M PEG, and 9.0x EV/Revenue (17.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus VCEL (9.4% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, VCEL carries 44.1% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.30β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.